lower tp follow speak
compani second opinion
maintain under-perform rate lower tp
updat model result incorpor detail
confer call follow call compani main concern
continu pressur humira eu sale face direct biosimilar
competit compani expect approach
alreadi forecast lower ex-u humira sale expect
decreas yoy follow moder declin
previou guidanc drop two-year
time period multipl biosimilar market addit one
come remain concern mid-term outlook forecast
declin ex-u rest stori includ
us humira sale seem solid stock clearli re-rat sinc
may wait clariti impact eu biosimilar
get construct
notabl model updat along updat humira sale also
meaning rais imbruvica estim follow quarter
also rais gross margin assumpt adjust sg
estim although still well compani expect
oper margin current forecast
valuat risk lower tp maintain
blue sky valuat
grey sky valuat target price dcf
wacc termin growth main risk call
includ stronger-than-expect humira sale especi eu and/or
success diversif busi away humira
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
price rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
 clarifi expect impact humira biosimilar
anticip step-down futur less though
compani offer deep discount tender countri sell countri
govern directli need commerci support though attract
profit standpoint see eros level expect
continu see step futur least late next year visibl
 walk away futur countri need give discount
humira profit product appropri calculu determin exit point and/or
negoti tri lock volum intern necessarili
said whether gave discount cant say countri walk
away bake aggress discount like due four biosimilar
compet time day one reiter ceo comment around higher discount
expect still expect doubl digit ep growth spite
 level discount think someon give becom unprofit
depend country/manufactur prohibit talk tender
one win one dont base whole host factor tender market
uniqu one compani win busi countri may forc switch cant offer
discount compet countri country-by-countri play-by-play
make decis make sens
 clarifi royalti roll humira
benefit given time patent expiri benefit
year next year
 detail orlissa sale
typic dont break product small week start break
soon launch go expect suppli free product rx trend
reflect volum current expect formulari januari almost
 right run rate think mavyret especi outsid us
volum declin annual fairli comfort price stabil
author gener price mavyret wacc price want make inroad
manag medicaid market mavyret busi basic two-
player market mostli game hope price stabil
commerci put take us base formulari
basic work wareh patient japan see big step
saw
 life-cycle duodopa
old drug composit matter patent hard manufactur get
approv competitor came quarter see compani flood
market specif ip protect
prostat endometriosi rest precoci puberti
 decis take cf asset galapago
think attract market compet invest pretti
modest point would move forward larger program see promis data
think current asset would competit focus third gen product
would better second gen could get market mid-
along efficaci opportun potenti improv side effect well
continu strong perform share gain
 chang pay quarter
cant read result predict spend pattern differ qoq
result impli beat imbruvica magnitud
us million except per share valu
sale
net interest incom
us million unless otherwis state
fx impact sale
us million unless otherwis state
us million unless otherwis state
pipelin total sale
us million unless otherwis state
product sold ex-amort
tax earn
average share outstand
dilut ep oper
compani mention price
